Abstract
At this year’s ESC congress in London, it was announced an update of the guidelines for the treatment of chronic heart failure with reduced left ventricular ejection fraction. Key change compared to last guidelines is withdrawal the long-term titration strategy and introducing a simpler and faster regimen based on four groups of drugs: blocking the renin–angiotensin–aldosterone system (ACE-I, ARNI), sodium-glucose co-transporter inhibitors (dapagliflozin, empagliflozin), β-adrenolytic drugs, mineralocorticoid receptor inhibitors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
